Janssen sees promising PRO data for prostate cancer therapy

pharmafile | May 27, 2021 | News story | |  Janssen, prostate cancer 

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC), seeing promising results.

The new PRO data showed that the addition of apalutamide to androgen deprivation therapy (ADT) maintained patients’ health-related quality of life (HRQoL) and did not worsen side effect burden, consistent with ADT alone.

The TITAN study previously demonstrated improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving apalutamide plus ADT.

Professor Axel Merseburger, Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck and investigator for TITAN, said: “Patients are often concerned about the added burden of side effects in their disease management. The latest findings from the TITAN clinical trial show us how we can improve patient overall survival without compromising on quality of life, an important step in the right direction for improved advanced prostate cancer care.”

Metastatic hormone-sensitive prostate cancer, also known as metastatic castration-sensitive prostate cancer, refers to prostate cancer that still responds to hormonal therapy and has spread beyond the prostate to other parts of the body.

HRQoL in both groups, patients who received apalutamide plus ADT and patients who received placebo plus ADT, was maintained throughout the study. Apalutamide plus ADT was also shown to maintain physical, social and family, emotional, functional, and mental well-being beyond two years, as assessed by Functional Assessment of Cancer Therapy-Prostate questionnaires.

Dr Catherine Taylor, EMEA Vice-president, Medical Affairs Therapy Area Strategy for Europe, Middle East and Africa, Johnson & Johnson Middle East FZ-LLC, said: “We are pleased to be able to share the patient reported outcome results from the TITAN study at ASCO this year.

“We know they are essential in providing meaningful context on the patient experience of treatment with apalutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer that enable healthcare professionals to make informed treatment decisions that are right for individual patients.

“These findings, along with the overall survival benefit, provide further evidence on apalutamide plus ADT as a first-line, therapeutic option for people living with mHSPC.”

Kat Jenkins

Related Content

Medical cannabis formulation kills prostate cancer in laboratory tests

Apollon Formularies have announced its medical cannabis formulations were shown to be effective in killing …


Janssen CLL treatment combination sees success in trials

Janssen has announced positive data from its Phase III GLOW study, with the combination of …

New NICE recommendation for Astellas prostate cancer drug

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen …

Latest content